BioLineRx (BLRX) Common Equity (2023 - 2025)
Historic Common Equity for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $19.5 million.
- BioLineRx's Common Equity rose 12966.49% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 12966.49%. This contributed to the annual value of $13.5 million for FY2024, which is 179.99% up from last year.
- BioLineRx's Common Equity amounted to $19.5 million in Q3 2025, which was up 12966.49% from $20.1 million recorded in Q2 2025.
- Over the past 5 years, BioLineRx's Common Equity peaked at $39.1 million during Q1 2023, and registered a low of $8.5 million during Q3 2024.
- Over the past 3 years, BioLineRx's median Common Equity value was $14.0 million (recorded in 2024), while the average stood at $17.8 million.
- Per our database at Business Quant, BioLineRx's Common Equity crashed by 6661.04% in 2024 and then surged by 12966.49% in 2025.
- Over the past 3 years, BioLineRx's Common Equity (Quarter) stood at $13.2 million in 2023, then increased by 1.8% to $13.5 million in 2024, then soared by 45.11% to $19.5 million in 2025.
- Its Common Equity was $19.5 million in Q3 2025, compared to $20.1 million in Q2 2025 and $20.9 million in Q1 2025.